Te of Regenerative Medicine, College of Medicine, Texas A M University, College Station, TX, USA; 2Department of Ophthalmology, Seoul National University Hospital, Seoul, Virus Protease Inhibitor Storage & Stability Republic of Korea; 3Laboratory of Ocular Regenerative Medicine and Immunology, Biomedical Study Institute, Seoul National University Hospital, Seoul, Republic of Korea; 4Department of Ophthalmology, Seoul National University Boramae Health-related Centre, Seoul, Republic of KoreaPT11.The CD24 receptor induces adjustments towards the surface protein composition of B cell microvesicles with variable effects on RNA and protein cargo D. Craig Ayre1, Ian C. Chute2, Andrew Joy2, David Barnett2, Andrew Hogan1, Marc P. Gruell3, Lourdes Pena-Castillo4, Andrew S. Lang3, Stephen M. Lewis5 and Sherri L. Christian1 Division of Biochemistry, Memorial University of Newfoundland, Newfoundland, Canada; 2Atlantic Cancer Research Institute, New Brunswick, Canada; 3Department of Biology, Memorial University of Newfoundland, Newfoundland, Canada; 4Departments of Pc ALDH1 review Science and Biology, Memorial University of Newfoundland, Newfoundland, Canada; 5Department of Chemistry and Biochemistry, Universitde Moncton, New Brunswick, CanadaAccumulating evidence shows that extracellular vesicles (EVs) produced by mesenchymal stem/stromal cells (MSCs) exert their therapeutic effects in a number of disease models. We previously demonstrated that MSCs suppress autoimmunity in models of sort 1 diabetes (T1D) and experimental autoimmune uveoretinitis (EAU). For that reason, we herein investigated the therapeutic prospective of MSC-derived EVs employing our established mouse models for autoimmune diseases affecting the pancreas and eye: T1D and EAU. The data demonstrate that MSC-derived EVs successfully protect against the onset of illness in each T1D and EAU. Also, the mixed lymphocyte reaction assay with MSC-derived EVs indicated that EVs suppress improvement of T helper 1 (Th1) cells by inhibiting activation of antigen presenting cells. These final results raise the possibility that MSC-derived EVs may perhaps be a novel option to cell therapy for autoimmune illnesses.Introduction: CD24 is often a cell surface receptor that promotes the apoptosis of developing B lymphocytes (B cells). We recently located that antibody stimulation of CD24 induces B cells to release CD24-bearing, plasma membrane-derived microvesicles (MVs). As these MVs haven’t previously been characterised we performed a systematic characterisation of B cell MVs from WEHI-231 B lymphoma cells. Methods: We examined CD24-induced adjustments to MV using TEM and nanoparticle tracking. Immediately after isolation with the Vn96 peptide, we analysedPT11.Exosomes derived from human autologous conditioned serum are nanocarriers for IL-6 and TNF-alfa Jamal Ghanam, Shaun Gaji, Mustafa Haddouti, Stephan Irsen, Julio Reinecke, Peter Wehling and Maria WeisshaarThursday Could 18,University of Applied Sciences Bonn-Rhein-Sieg, Sankt Augustin, GermanyIntroduction: Regional injection of autologous conditioned serum (ACS) is actually a prevalent therapeutic regimen for rheumatoid and orthopaedic illnesses (ODs). ACS is obtained by incubating of patients’ blood and subsequent centrifugation. Through blood incubation, immune cells generate high amounts of development things and cytokines, including interleukin-1 receptor antagonist (IL-1ra), interleukin-6 (IL-6), tumour necrosis issue alpha (TNF-) and transforming growth element beta 1 (TGF-1). The aim of this study was to analyse exosomes release into ACS and their cytokine cargo. Procedures.